Galena Biopharma, Inc. Message Board
-
ASCO !
TIC TOC!Sentiment: Strong Buy
-
TIME IS RUNNING OUT, YOU SHOULD KNOW YOU CAN'T LIVE A LIE!
TIC TOC TIC TOK tic toc!Sentiment: Strong Buy
-
sHORTY must buy to cover!
NORTH!Sentiment: Strong Buy
-
Do not reply to any basher! IF ON TOP ASK FOR LINK!
Sentiment: Strong Buy
-
Look at the who's who!
Meeting:
2013 ASCO Annual Meeting
Abstract No:
LBA509
Citation:
J Clin Oncol 31, 2013 (suppl; abstr LBA509)
Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2013 Annual Meeting but not presented at the Meeting, can be found online only.
Author(s): Gabriel N. Hortobagyi, Martine J. Piccart-Gebhart, Hope S. Rugo, Howard A. Burris, Mario Campone, Shinzaburo Noguchi, Alejandra T. Perez, Ines Deleu, Mikhail Shtivelband, Louise Provencher, Norikazu Masuda, Shaker R. Dakhil, Ian Anderson, David Chen, Amy Damask, Alan Huang, Robert McDonald, Tanya Taran, Tarek Sahmoud, José Baselga; Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX; Jules Bordet Cancer Institute, Brussels, Belgium; University of California, San Francisco, San Francisco, CA; Sarah Cannon Research Institute, Nashville, TN; CLCC René Gauducheau, Centre de Recherche en Cancerologie, Nantes Saint Herblain, France; Osaka University, Osaka, Japan; Memorial Cancer Institute, Breast Cancer Program, Hollywood, FL; AZ Nikolaas, Sint-Niklaas, Belgium; Ironwood Cancer and Research Centers, Chandler, AZ; Centre des Maladies du Sein Deschênes-Fabia, Hôpital du Saint-Sacrement, Quebec City, QC, Canada; Osaka National Hospital, Osaka, Japan; Cancer Center of Kansas, Wichita, KS; Redwood Regional Oncology Center, Santa Rosa, CA; Novartis Pharmaceuticals, Oncology, Florham Park, NJ; Novartis Institutes for BioMedical Research, Cambridge, MA; Oncology Translational Medicine, Novartis Institute for Biomedical Research, Cambridge, MA; Novartis Institutes for BioMedical Research, Inc., Cambridge, MA; Novartis Pharmaceuticals Corp, Florham Park, NJ; Novartis Pharmaceuticals Corp, East Hanover, NJ; Memorial Sloan-Kettering Cancer Center, New York, NY
Abstract DisclosuresSentiment: Strong Buy
-
To buy some TBIO and GALE!
Sentiment: Strong Buy
-
TBIO and GALE will have abstracts that will move the their stock!
Sentiment: Strong Buy
- Reply to
VVUS is being taken up so they can take profits and get out
by malph_ralph •May 20, 2013 12:18 PMBUYING (TBIO) and (GALE) for a nice at ASCO.
Sentiment: Strong Buy
-
This is bigger then you know!
Dr. Geert Cauwenbergh, ( with an impeccable history of success plus over 20 years as head of J&J's skin care division.
successful sales of two biotech companies, groundbreaking RNAi technology with a novel delivery method, Dr. Craig Mello Nobel prizewinner for discovery of RNAi and who remains on the advisory board of RXI, solid book of IP along with multiple drugs in the pipeline, Potential blockbuster in rxi-109 showing stellar results to date,
Financing and cooperation with Dr Frost, self made multi billionaire in biotech, Available funds for Ph2 into 2015.........Sentiment: Strong Buy
-
Type message
Galena Biopharma, Inc. (GALE)
-NasdaqCM
2.5250 Up 0.0950(3.91%) 10:28AM EDT - Nasdaq Real Time Price
Add to Portfolio
Major Holders Get Major Holders for:
Breakdown
% of Shares Held by All Insider and 5% Owners: 1%
% of Shares Held by Institutional & Mutual Fund Owners: 8%
% of Float Held by Institutional & Mutual Fund Owners: 8%
Number of Institutions Holding Shares: 46
Major Direct Holders (Forms 3 & 4)
Holder Shares Reported
SCHWARTZ MARK W. 462,688 Dec 30, 2012
KHVOROVA ANASTASIA 137,482 Sep 23, 2011
HILLSBERG SANFORD 136,376 Nov 1, 2012
AHN MARK J 100,246 Dec 30, 2012
LEE KWANG 5,000 Dec 6, 2011
Top Institutional Holders
Holder Shares % Out Value* Reported
BlackRock Institutional Trust Company, N.A. 1,920,481 2.30 4,033,010 Mar 31, 2013
Vanguard Group, Inc. (The) 1,847,794 2.21 3,880,367 Mar 31, 2013
AQR Capital Management, LLC 618,600 0.74 946,458 Dec 31, 2012
Morgan Stanley 550,616 0.66 1,156,293 Mar 31, 2013
Susquehanna International Group, LLP 510,781 0.61 1,072,640 Mar 31, 2013
Sabby Management, LLC 342,633 0.41 524,228 Dec 31, 2012
Geode Capital Management, LLC 297,344 0.36 624,422 Mar 31, 2013
UBS AG 233,257 0.28 489,839 Mar 31, 2013
BlackRock Fund Advisors 164,849 0.20 346,182 Mar 31, 2013
Bank of New York Mellon Corporation 156,633 0.19 328,929 Mar 31, 2013
Top Mutual Fund Holders
Holder Shares % Out Value* Reported
Vanguard Total Stock Market Index Fund 1,098,769 1.32 1,681,116 Dec 31, 2012
AQR Funds-AQR Diversified Arbitrage Fd 510,000 0.61 780,300 Dec 31, 2012
Vanguard Extended Market Index Fund 450,875 0.54 689,838 Dec 31, 2012
Spartan Extended Market Index Fund 229,872 0.28 482,731 Mar 31, 2013
iShares Russell Micro Cap (TM) Index Fund 163,057 0.20 342,419 Mar 31, 2013
Spartan Total Market Index Fund 57,499 0.07 120,747 Mar 31, 2013
Advanced Series Tr-AST Academic Strategies Asset Allocation 54,000 0.06 82,620 Dec 31, 2012
Vanguard Balanced Index Fund 36,836 0.04 56,359 Dec 31, 2012
Claymore ETF Tr-Wilshire Micro Cap ETF 28,690 0.03 60,249 Mar 31, 2013
Vantagepoint Mid/Small Company Index Fund 11,942 0.01 18,271 Dec 31, 2012Sentiment: Strong Buy
-
More to come we are headed north!
Sentiment: Strong Buy
- Reply to
News: Galena Biopharma Acquires Abstral(R) (fentanyl) Sublingual Tablets in U.S.
by carmitrascu •May 1, 2013 11:50 AMPAYDAY!
i HEAR THE TRAIN A COMING!Sentiment: Strong Buy
- Reply to
News: Galena Biopharma Acquires Abstral(R) (fentanyl) Sublingual Tablets in U.S.
by carmitrascu •May 1, 2013 11:50 AMTime to buy before GALE takes off!
"Abstral is a significant advance for patients with breakthrough cancer pain and the TIRF REMS program is an essential element to prescribing Abstral® to ensure that patients are safely and effectively treated," stated Mark J. Ahn, Ph.D., Galena's President and Chief Executive Officer. "Abstral's sublingual TIRF REMS program served as a model for the current shared TIRF REMS, and we look forward to launching our product in the U.S. this year."
The presentation also concluded that the shared TIRF REMS program aims to minimize risk by limiting the dispensing of medication to appropriate patients, preventing inappropriate conversion between fentanyl products, avoiding accidental exposure, and providing education on medication-related risks.
"The TIRF REMS program provides my practice with the ability to choose the appropriate product based on my patient's needs, and Abstral is an essential drug as part of this arsenal to effectively treat my cancer patients with breakthrough pain," added Srinivas R. Nalamachu, M.D., International Clinical Research Institute, Overland Park, Kansas.
About Abstral® (fentanyl) Sublingual Tablets
Abstral® (fentanyl) Sublingual Tablets are an important new treatment option for inadequately controlled breakthrough cancer pain (BTcP) which impact 40%-80% of cancer patients. Abstral is approved by the FDA, and is a sublingual (under the tongue) fentanyl tablet indicated only for the management of breakthrough pain in patients with cancer, 18 years of age and older, who are already receiving, and who are tolerant to, opioid therapy for their persistent baseline cancer pain. The innovative Abstral formulation delivers the analgesic power and increased bioavailability of micronized fentanyl in a more convenient sublingual tablet which rapidly dissolves under the tongue in seconds, provides rapid relief of breakthrough pain in minutes, and matches the duration of the entire pain episode.Sentiment: Strong Buy
-
HERE A BASHER FROM ANOTHER BOARD!
Notice the date!
keith.sims 1 post | Last Activity: 5 minutes ago Member since: May 17, 2013Sentiment: Strong Buy
-
NEW BORN!
keith.sims 1 post | Last Activity: 5 minutes ago Member since: May 17, 2013Sentiment: Strong Buy
-
Cherry Picking Mined Data From Failed P2 Trial
22 hours ago by stock#$%$ 0/3 4 13 seconds ago by zahnd9898
Read it and Weep
May 9, 2013 10:17 AM by stock#$%$ 3/10 16 5 minutes ago by nickshelley396
POS Reject Drugs Acquired for Pennies and Then Peddled to Imbeciles for $200M+
May 14, 2013 10:50 AM by stock#$%$ 2/2 8 26 minutes ago by stock#$%$
I Bet You See $00.20 and Never See $4.00
28 minutes ago by stock#$%$ 0/0 0 28 minutes ago by stock#$%$
ONTY Lung Cancer Vaccine Fails in P3 (Stock Down 25%)
30 minutes ago by stock#$%$Sentiment: Strong Buy
-
link link LINK LINK! KINK! THIS IS IN PH.III
You will pay for this lie!!!Sentiment: Strong Buy
-
go gale go!
Sentiment: Strong Buy
- Reply to
NeuVax - The First Breast Cancer Vaccine in Phase III FDA Clinical Trials
by danindenver33 •Jan 20, 2013 1:32 PMF.D.A. is on our side.
I WAIT I WAIT THE PAYDAY WILL BE HUGE!Sentiment: Strong Buy
- Reply to
IGXT (Mcap $31 M) 4x FDA approvals within 1 Year & Profitable this Year = 10++ Bagger Potential !!!
by medicalstars •May 6, 2013 10:41 AMNEW BORN!
medicalstars 56 posts | Last Activity: May 9, 2013 1:35 PM Member since: Apr 1, 2013